Trop2: Jack of All Trades, Master of None

0536531 - BFÚ 2021 RIV CH eng J - Článek v odborném periodiku
Lenart, S. - Lenart, P. - Šmarda, J. - Remsik, J. - Souček, Karel - Beneš, P.
Trop2: Jack of All Trades, Master of None.
Cancers (Basel). Roč. 12, č. 11 (2020), č. článku 3328. E-ISSN 2072-6694
Grant CEP: GA MZd(CZ) NV17-28518A; GA MZd(CZ) NV18-08-00245
Institucionální podpora: RVO:68081707
Klíčová slova: antibody-drug conjugate * squamous-cell carcinoma * signal transducer 2 * sacituzumab govitecan * prostate-cancer * lung-cancer
Obor OECD: Oncology
Impakt faktor: 6.639, rok: 2020
Způsob publikování: Open access
http://apps.webofknowledge.com/InboundService.do?customersID=Alerting&mode=FullRecord&IsProductCode=Yes&product=WOS&Init=Yes&Func=Frame&DestFail=https%3A%2F%2Fwww.webofknowledge.com&action=retrieve&SrcApp=Alerting&SrcAuth=Alerting&SID=C1pXEQmefCtg1cvGeE2&UT=WOS%3A000592751100001

Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins, however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.
Trvalý link: http://hdl.handle.net/11104/0314304